In cooperation with SCIEX, Thomas Kofoed gives a short speak on ADC conjugation analysis at the coming World ADC meeting in London. Meet him at Sciex stand no9 for more information on the the subject of Antibody drug conjugates (ADCs).
The World ADC meetings provide superb networking for the scientific community working on ADCs within Biotech, Pharma and Academia.
WORLD ADC website: https://worldadc-europe.com/
What are ADCs?
ADCs are site-directed monoclonal antibodies coupled to cytotoxins used for targeted treatment of cancer. It is important to know the drug-antibody-ratio (DAR) because of dosing. However, it is often difficult to control. Both in manufacturing and analytical characterization.
In a recent Eurostars project on ADCs, Alphalyse worked with the Swiss life science tool company ChromaCon. The aim was to improve their MCSGP technology for purification of ADC’s. We also improved our own analytical methods. These include both detailed ADC characterization and also their drug-antibody-ratios (DAR).